Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

EPIGENETICS

SETDB1, a new target for immunotherapy

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

Original article

  1. Griffin, G. K. et al. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature https://doi.org/10.1038/s41586-021-03520-4 (2021)

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ulrike Harjes.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Harjes, U. SETDB1, a new target for immunotherapy. Nat Rev Cancer 21, 412 (2021). https://doi.org/10.1038/s41568-021-00373-x

Download citation

Search

Quick links